ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1919

Financial insecurity and discrimination are associated with patient-reported quality of life in patients with SLE
Abstract Number: 1850

First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
Abstract Number: 1677

First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
Abstract Number: 2653

First Prospective Evaluation of Recombinant Herpes Zoster Vaccine in Systemic Sclerosis: Immunogenicity, Safety, and Disease Activity Outcomes
Abstract Number: 1462

Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
Abstract Number: 0821

Flipping The Switch – Classical Complement Activation closely linked to IFN-signalling in Stills Disease
Abstract Number: 2080

Foot laterality does not modify outcome of knee and/or hip osteoarthritis
Abstract Number: 0447

Foot-pressure distribution method for detection of foot joint arthritis in patients with rheumatic diseases
Abstract Number: 0059

Formyl Peptide Receptor 1 (FPR1) Influences Arthritis Severity in a Sex- and Compartment-Specific Manner
Abstract Number: 1275

Fostering connections in Pediatric Rheumatology: A Narrative medicine intervention
Abstract Number: LB10

Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program
Abstract Number: 0969

FOXO1 Mediated Polysialic Acid Dysregulation in Severe Systemic Sclerosis (SSc): A Novel Biomarker and Therapeutic Target?
Abstract Number: 0992

FoxP3Lo CD4+ T cells are functionally suppressive and expanded in the immune-mediated fibrotic diseases IgG4-related disease and systemic sclerosis
Abstract Number: 2119

Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity
Abstract Number: 0246

Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].